Ceapro Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

  • Maintained production operations during COVID-19 pandemic, providing customers with essential products and completing integration of manufacturing site, while ensuring the health and safety of employees
  • Substantially increased sales, net profits and cash generated from operations during the year 2020, representing one of Ceapro’s best performances in company history
  • R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19

EDMONTON, Alberta, April 22, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2020.

“We could not be prouder of our resilient employees who worked tirelessly to deliver one of the best ever performances in the Company’s history during such a stressful year marked by the ongoing COVID-19 pandemic. While ensuring safety of our employees as our first priority, we were able to secure business continuity by putting more emphasis on production operations to serve our customers in the cosmetic sector. This approach, which has resulted in significant increase in sales, net profits and cash on hand, also allowed us to maintain investments in Research and Development as per our strategy to expand Ceapro’s business model from a contract manufacturer/commodity company to a high-value life science/biopharmaceutical company offering innovative products and delivery systems to the healthcare sector,” stated Gilles Gagnon, M.Sc., MBA, President and CEO, of Ceapro.

“In addition to excellent financial and operational results, main highlights of the year include the development of beta glucan from yeast and its potential as an inhalable therapeutic for COVID-19 patients as well as the development of new chemical complexes through the use of the PGX Technology. We are thrilled with the achievements made in 2020,” added Mr. Gagnon.

2020 Corporate and Operational Highlights

Pipeline Development

Oat Beta Glucan:

  • Resumed enrollment of patients for the clinical trial with beta glucan as a cholesterol reducing natural pharmaceutical product. The study will enroll approximately 264 patients. To date, two thirds of the patients have been screened and randomized.

  • Received approval from Health Canada for an amendment to the protocol to allow evaluation of subjects with confirmed pathophysiological condition of hyperlipidemia who voluntarily request to be treated with beta glucan only, without regular dosing of statins. This significant change, allowing patients to receive beta glucan as a stand-alone therapy, has accelerated patient enrollment and is expected to expand the target addressable patient population.


  • Announced the publication of positive results from study evaluating avenanthramides in exercise-induced inflammation in the international, peer-reviewed Journal of the International Society of Sports Nutrition. Positive results support anti-inflammatory claims for avenanthramides as a nutraceutical product and pave the way for a Phase 1 clinical trial as a potential pharmaceutical product.

  • Continued to monitor stability studies for liquid avenanthramides produced at a new manufacturing site as well as for the pharmaceutical-grade dry powder formulation of avenanthramides to be used in a human Phase 1 bioavailability and safety study.

New Products:


  • Received approval from Health Canada Controlled Substances and Cannabis Branch for a five-year research license with medical cannabis for the formulation of unique solid cannabinoid delivery systems using PGX technology.

Yeast Beta Glucan (YBG)

  • Developed an optimal formulation of YBG coming from various sources.

  • Confirmed capability of PGX Technology to optimize and standardize the size and morphology of yeast beta-glucan (PGX-YBG) suitable for lung inhalation.

  • Achieved the first milestones in successful development of PGX-processed yeast beta glucan product as a potential inhalable therapeutic for COVID-19 and other fibrotic endpoint diseases of the lung.

  • Conducted an in-vitro study with human cell lines demonstrating that PGX-YBG obtained from different sources exhibited significant stimulatory effect on human immune response through activation of beta glucan specific Dectin 1 receptors.

  • Ongoing PGX-YBG project with McMaster University conducted in parallel for naïve and preclinical animal models. To date, no safety issues have been encountered. The preclinical phase has been extended to identify the maximum tolerated dose.

  • Conducted additional in vitro PGX-YBG dose response study to correlate with upcoming McMaster animal study results. YBG induces immunomodulation without affecting inflammation pathways. This product is poised to become a key strategic asset for the Company.

New Chemical Complexes:

  • Developed new PGX-dried chemical complexes like sodium alginate and gum arabic impregnated with co-enzyme Q10 (CoQ10). Positive results published in peer-reviewed journals demonstrate the versatility of the PGX Technology and the potential to develop significant bioactive delivery systems. Key learnings from these studies pave the way for the scale-up of the technology at the commercial level.

  • Subsequent to year-end, Ceapro announced the successful completion of a long-term research program conducted with University of Alberta. This screening program allowed Ceapro to retain the most promising products and expand the PGX-based products pipeline.


  • Performed significant technical upgrades of PGX pilot plant in Edmonton to allow production of yeast beta glucan for a potential clinical trial with COVID-19 patients.

  • Completed a feasibility study for the commercial scale up of the PGX Technology. Several manufacturers and existing supercritical plants were contacted in 2020 for the choice of equipment and location. Given excellent results obtained with the new yeast beta glucan product, it became clear that location of the first large scale PGX unit should be close to the best source of raw material which was found in Germany where the Company also acquired pieces of equipment suitable for the assembling of such unit. Production at the retained site will be mostly for the commercialization of yeast beta glucan as an immune booster and for alginate as a carrier for other bioactives.

  • Initiated installment in Edmonton of a commercial scale unit for impregnation of bioactives with PGX-processed biopolymers.

  • Pursued research collaboration projects with University of Alberta and McMaster University for the impregnation of various bioactives using PGX-processed biopolymers as potential delivery systems for multiple applications in healthcare.

Bioprocessing Operations

  • Completed the integration of production operations under one roof in Edmonton. Ceapro’s dedicated production team successfully responded to the growing market demand for the cosmeceutical base business by producing over 250 metric tons of active ingredients in 2020, a 25% increase over the previous year.

  • Received renewal of the Site License from the Health Canada Natural Product Directorate. This License enables the Company to manufacture, package, label, release and distribute final products.


  • Fully repaid loan with Agriculture Financial Services Corporation.

  • Announced expansion of a grant from National Research Council of Canada for the optimization and mass production of yeast beta glucan as a potential inhalable therapeutic for COVID-19 and other fibrotic end-point disease of the lung.

  • Pursued out-licensing discussions for PGX-processed new chemical complexes.

  • Secured DTC Eligibility for publicly traded shares under Ticker OTCQZ: CRPOF and to expand Company exposure to other markets with an emphasis in USA.

Financial Highlights for the Fourth Quarter and the Full Year 2020 Ended December 31, 2020

  • Total sales of $2,706,000 for the fourth quarter of 2020 and $15,121,000 for the full year of 2020 compared to $3,721,000 and $12,880,000 for the comparative periods in 2019. The 17% increase in revenue for the full year 2020 results from an 33% increase in sales of avenanthramides (mostly made to USA) partially offset by a 16% decrease in sales of beta glucan.

  • Net loss of $539,000 for the fourth quarter of 2020 and a net profit of $1,856,000 for the full year of 2020 compared to a net profit of $166,000 and a net loss of $1,133,000 for the comparative periods in 2019, a year over year improvement of $2,989,000 Third and fourth quarter 2020 were marked by the completion of the decommissioning of Leduc manufacturing site and the final integration of production operations in the Edmonton facility. These time-consuming moves resulted in some necessary adjustments in equipment at the new site. It also required additional training of relocated employees.

  • Cash generated from operations of $4,453,000, for the full year 2020 vs cash generated from operations of $882,000 for the full year 2019.

  • Positive working capital balance of $7,659,000 as of December 31, 2020.

“I strongly believe 2021 holds a lot of opportunity for Ceapro. Our focus remains on the health and safety of our associates during this COVID-19 pandemic crisis, followed by business continuity. Depending on the evolution of the COVID-19 pandemic, we expect Ceapro’s cosmeceuticals base business to continue to grow and provide positive operating cash flows to support the expansion to a new business model from a contract manufacturer to a biopharmaceutical development company involved in nutraceuticals and pharmaceuticals. Based on a very solid foundation, a highly competent team, a healthy balance sheet and a very strong technology and product portfolio with the potential to access key large markets, we have all the key components for success,” concluded Mr. Gagnon.

Consolidated Balance Sheets    
  December 31, December 31,
  2020 2019
  $ $
Current Assets    
Cash and cash equivalents 5,369,029 1,857,195
Trade receivables 2,019,723 3,659,541
Other receivables 102,224 46,812
Inventories (note 3) 1,210,079 669,005
Prepaid expenses and deposits 348,845 178,908
  9,049,900 6,411,461
Non-Current Assets    
   Investment tax credits receivable 607,700 607,700
Deposits 82,124 85,755
Licences (note 4) 18,514 21,477
Property and equipment (note 5) 18,591,189 19,764,122
Deferred tax assets (note 14 (b)) 874,304 378,643
  20,173,831 20,857,697
TOTAL ASSETS 29,223,731 27,269,158
Current Liabilities    
Accounts payable and accrued liabilities 1,067,622 1,291,204
Current portion of long-term debt (note 6) - 111,865
Current portion of lease liabilities (note 7) 250,658 265,123
Current portion of CAAP loan (note 9) 72,263 72,942
  1,390,543 1,741,134
Non-Current Liabilities    
Long-term lease liabilities (note 7) 2,648,917 2,775,627
CAAP loan (note 9) - 61,580
Deferred tax liabilities (note 14 (b)) 874,304 378,643
  3,523,221 3,215,850
TOTAL LIABILITIES 4,913,764 4,956,984
Share capital (note 8 (b)) 16,511,067 16,401,677
Contributed surplus (note 8 (e)) 4,682,393 4,650,090
Retained earnings 3,116,507 1,260,407
  24,309,967 22,312,174
TOTAL LIABILITIES AND EQUITY 29,223,731 27,269,158

Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
  2020   2019  
Year Ended December 31, $ $
Revenue (note 16) 15,121,282   12,880,006  
Cost of goods sold 7,498,996   7,434,654  
Gross margin 7,622,286   5,445,352  
Research and product development 1,881,883   2,393,607  
General and administration 3,282,754   2,952,488  
Sales and marketing 111,044   425,230  
Finance costs (note 12) 231,271   260,684  
Income (loss) from operations 2,115,334   (586,657 )
Other expenses (note 11) (259,234 ) (549,379 )
Income (loss) before tax 1,856,100   (1,136,036 )
Income taxes    
   Current tax recovery -   -  
   Deferred tax benefit -   3,408  
Income tax benefit -   3,408  
Total comprehensive income (loss) for the year 1,856,100   (1,132,628 )
Net income (loss) per common share (note 21):    
Basic 0.02   (0.01 )
Diluted 0.02   (0.01 )
Weighted average number of common shares outstanding (note 21):    
Basic 77,594,629   77,188,505  
Diluted 78,143,033   77,188,505  

Consolidated Statements of Cash Flows    
  2020   2019  
Year Ended December 31, $ $
Net income (loss) for the year 1,856,100   (1,132,628 )
Adjustments for items not involving cash    
Finance costs 153,538   171,249  
Transaction costs 1,108   4,187  
Depreciation and amortization 1,841,033   1,831,744  
Foreign exchange gain on long-term debt -   (307 )
Accretion 21,625   30,248  
Deferred tax benefit -   (3,408 )
Share-based payments 136,796   212,517  
Net income (loss) for the year adjusted for non-cash items 4,010,200   1,113,602  
Trade receivables 1,639,818   (644,197 )
Other receivables (55,412 ) 87  
Inventories (541,074 ) 41,703  
Prepaid expenses and deposits (88,839 ) 154,106  
Accounts payable and accrued liabilities relating to operating activities (358,136 ) 388,064  
Total changes in non-cash working capital items 596,357   (60,237 )
Net income (loss) for the year adjusted for non-cash and working capital items 4,606,557   1,053,365  
Interest paid (153,538 ) (171,249 )
Purchase of property and equipment (528,707 ) (332,186 )
Purchase of leasehold improvements (12,870 ) (6,007 )
Proceeds from sale of equipment 353   -  
Deposits relating to investment in equipment (77,467 ) 187,790  
Accounts payable and accrued liabilities relating to investing activities 134,554   (46,738 )
Stock options exercised 4,897   17,284  
Repayment of long-term debt (112,973 ) (339,321 )
Repayment of CAAP loan (83,884 ) (83,884 )
Repayment of lease liabilities (265,088 ) (265,993 )
Increase in cash and cash equivalents 3,511,834   13,061  
Cash and cash equivalents at beginning of the year 1,857,195   1,844,134  
Cash and cash equivalents at end of the year 5,369,029   1,857,195  

The complete financial statements are available for review on SEDAR at https://sedar.com/Ceapro and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Primary Logo

Source: Ceapro Inc.